Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 9Endocrine 9Thoracic 2Plasma cell 2Other hematologic neoplasm 2Gastrointestinal 2CNS 2Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Neoplasms 3Melanoma 3Lung Neoplasms 3Glioma 3Thyroid Carcinoma, Anaplastic 2Ovarian Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sexual Dysfunction, Physiological 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Melanoma, Cutaneous Malignant 1Lymphoproliferative Disorders 1Lymphoma 1Laryngeal Neoplasms 1Histiocytosis, Langerhans-Cell 1Gastrointestinal Neoplasms 1

Interventions

dabrafenib 2Trastuzumab 2zimberelimab 1vandetanib 1trametinib 1tislelizumab 1tipifarnib 1surufatinib 1spartalizumab 1sargramostim 1cobimetinib 1aldesleukin 1Vemurafenib 1Tamoxifen 1Radiotherapy 1PLX8394 1Interleukin-12 Subunit p35 1Interleukin-12 1Gefitinib 1Doxorubicin 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × dabrafenib × Thoracic × Clear all
NCT07440290 2026-02-27

DETERMINE

Cancer Research UK

Phase 2/3 Not yet recruiting
30 enrolled
CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

JS InnoPharm, LLC

Phase 1 Suspended
71 enrolled
DermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡